UY38213A - Derivados de neuroesteroides y usos de estos - Google Patents
Derivados de neuroesteroides y usos de estosInfo
- Publication number
- UY38213A UY38213A UY38213A UY38213A UY38213A UY 38213 A UY38213 A UY 38213A UY 38213 A UY38213 A UY 38213A UY 38213 A UY38213 A UY 38213A UY 38213 A UY38213 A UY 38213A
- Authority
- UY
- Uruguay
- Prior art keywords
- neurosteroids
- derivatives
- derived
- novel
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862667100P | 2018-05-04 | 2018-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38213A true UY38213A (es) | 2019-10-31 |
Family
ID=68384780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY38213A UY38213A (es) | 2018-05-04 | 2019-05-03 | Derivados de neuroesteroides y usos de estos |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190337975A1 (https=) |
| EP (1) | EP3788055A4 (https=) |
| JP (1) | JP2021523938A (https=) |
| CN (1) | CN112823164A (https=) |
| AR (1) | AR116659A1 (https=) |
| AU (1) | AU2019264032A1 (https=) |
| CA (1) | CA3099089A1 (https=) |
| PY (1) | PY1934080A (https=) |
| TW (1) | TW202014192A (https=) |
| UY (1) | UY38213A (https=) |
| WO (1) | WO2019211668A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| ES2848823T3 (es) | 2013-08-23 | 2021-08-12 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| US10577390B2 (en) | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| ME03809B (me) | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| WO2016123056A1 (en) | 2015-01-26 | 2016-08-04 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| HK1258616A1 (zh) | 2016-03-08 | 2019-11-15 | Sage Therapeutics, Inc. | 神经活性类固醇、组合物、及其用途 |
| US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| CR20240234A (es) | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| CN115348864A (zh) * | 2020-02-05 | 2022-11-15 | 纯技术Lyt股份有限公司 | 神经甾体的脂质前药 |
| MX2022010620A (es) * | 2020-02-27 | 2022-11-30 | Brii Biosciences Inc | Profarmacos de esteroides neuroactivos. |
| IL315509A (en) * | 2022-03-18 | 2024-11-01 | Marinus Pharmaceuticals Inc | Genaxolone medication matrims |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB748846A (en) * | 1953-10-28 | 1956-05-09 | Vitamins Ltd | A process for the manufacture of pregnan-3(-a)-ol-20-one and derivatives thereof |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| KR100338287B1 (ko) * | 1994-02-14 | 2002-11-30 | 푸르듀 파머 리미티드 | 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난 |
| US20060009432A1 (en) * | 2004-07-09 | 2006-01-12 | Roger Whiting | Use of neurosteroids to treat neuropathic pain |
| WO2011120044A1 (en) * | 2010-03-26 | 2011-09-29 | Duke University | Conjugated neuroactive steroid compositions and methods of use |
| FR2973031B1 (fr) * | 2011-03-23 | 2013-11-29 | Univ Strasbourg | Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique |
| US20170022245A1 (en) * | 2013-11-26 | 2017-01-26 | Biopharma Works | Ganaxolone derivatives for treatment of central nervous systems disorders |
| EP3641779B1 (en) * | 2017-06-23 | 2024-02-28 | The Board of Trustees of the University of Illinois | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
| CN109666055A (zh) * | 2017-10-16 | 2019-04-23 | 张家口华健致远生物科技有限公司 | 调节中枢神经治疗抑郁症的化合物及其用途 |
-
2019
- 2019-05-03 US US16/403,100 patent/US20190337975A1/en not_active Abandoned
- 2019-05-03 WO PCT/IB2019/000517 patent/WO2019211668A2/en not_active Ceased
- 2019-05-03 CA CA3099089A patent/CA3099089A1/en active Pending
- 2019-05-03 TW TW108115447A patent/TW202014192A/zh unknown
- 2019-05-03 AU AU2019264032A patent/AU2019264032A1/en not_active Abandoned
- 2019-05-03 EP EP19796480.2A patent/EP3788055A4/en not_active Withdrawn
- 2019-05-03 AR ARP190101187A patent/AR116659A1/es not_active Application Discontinuation
- 2019-05-03 PY PY201901934080A patent/PY1934080A/es unknown
- 2019-05-03 UY UY38213A patent/UY38213A/es unknown
- 2019-05-03 JP JP2021510564A patent/JP2021523938A/ja active Pending
- 2019-05-03 CN CN201980033110.9A patent/CN112823164A/zh active Pending
-
2021
- 2021-08-02 US US17/392,004 patent/US20210363173A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019211668A3 (en) | 2019-12-12 |
| TW202014192A (zh) | 2020-04-16 |
| EP3788055A2 (en) | 2021-03-10 |
| CA3099089A1 (en) | 2019-11-07 |
| AR116659A1 (es) | 2021-06-02 |
| PY1934080A (es) | 2019-11-08 |
| AU2019264032A1 (en) | 2020-12-03 |
| EP3788055A4 (en) | 2022-03-30 |
| US20190337975A1 (en) | 2019-11-07 |
| JP2021523938A (ja) | 2021-09-09 |
| CN112823164A (zh) | 2021-05-18 |
| WO2019211668A2 (en) | 2019-11-07 |
| US20210363173A1 (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38213A (es) | Derivados de neuroesteroides y usos de estos | |
| CL2020001547A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa. | |
| AR132627A2 (es) | Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos | |
| MX392673B (es) | Derivados de pirazol como inhibidores de malt1 | |
| JOP20190022B1 (ar) | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري | |
| MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
| CL2019001744A1 (es) | Derivados de benzoxazol como inmunomoduladores. | |
| MX2017003695A (es) | Pirimidinonas como inhibidores del factor xia. | |
| CO2018000660A2 (es) | Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol | |
| MX377277B (es) | Derivados de fenoximetilo. | |
| CO2018004964A2 (es) | Compuestos útiles como inmunomoduladores | |
| MX377124B (es) | Compuestos heterociclicos y usos de los mismos. | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| MX382122B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX375863B (es) | Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr) | |
| MX2018014114A (es) | Derivados del sobetiroma. | |
| SV2017005381A (es) | Compuestos de imidazopiridazina | |
| MX2017006565A (es) | Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr). | |
| CR20170008A (es) | Compuestos de [1,2,4] triazol e imidazol sustituidos | |
| CO2022002336A2 (es) | Compuestos heterocíclicos | |
| MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
| UY36070A (es) | Triterpenoides con actividad inhibidora de la maduración de hiv | |
| MX2017005578A (es) | Métodos de administración de composiciones de amantadina. | |
| UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| JOP20200030A1 (ar) | مركب خماسي الحلقة |